Karyopharm Therapeutics Inc. (KPTI) News

Karyopharm Therapeutics Inc. (KPTI): $8.31

-0.06 (-0.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter KPTI News Items

KPTI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KPTI News Highlights

  • 500 - Internal server error
  • Over the past 27 days, the trend for KPTI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about KPTI are MS.

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis. These company-sponsored

Yahoo | July 28, 2021

Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 27, 2021

Karyopharm Therapeutics Inc (KPTI): Are Hedge Funds Right About This Stock?

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Yahoo | July 20, 2021

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

No summary available.

Karyopharm Therapeutics | July 1, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and for the clinical development of Karyopharm'

Yahoo | June 24, 2021

FDA approves selinexor for refractory or relapsed multiple myeloma

On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

US Food and Drug Administration | June 11, 2021

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with

Benzinga | June 9, 2021

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

Antengene's Partner, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), announced updated data of eltanexor for the treatment of patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Yahoo | June 9, 2021

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association 2021 Virtual Congress taking place June 9-17, 2021.

BioSpace | June 8, 2021

Antengene''s Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 /PRNewswire/ -- Antengene''s Partner, Karyopharm

PR Newswire | June 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6443 seconds.